special feature
clinical trials: patients at the center
special editorial submitted by champion steward partner janssen pharmaceutical companies of johnson & johnson 10 connexions
G
Good health for mothers and babies in the womb creates the foundation for a vibrant childhood and future. Very rarely, despite maintaining good health, a mother and developing baby can have different blood types that are not compatible, putting them at risk for a disorder known as hemolytic disease of the fetus and newborn (HDFN), which affects 3 to 80 in 100,000 patients per year in the U.S.1 In HDFN, a mother’s immune system identifies the fetal red blood cells as “foreign” and mounts a response that can cause serious health complications for the fetus.
